Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2002-04-05
2010-06-15
Bunner, Bridget E (Department: 1646)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C424S134100, C424S156100, C424S277100, C435S372000, C530S387300
Reexamination Certificate
active
07736652
ABSTRACT:
The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion proteins and innate and/or exogenous antigenic proteins are also provided.
REFERENCES:
patent: 5650150 (1997-07-01), Gillies
patent: 5977322 (1999-11-01), Marks et al.
patent: 6194177 (2001-02-01), Campbell et al.
patent: 6617135 (2003-09-01), Gillies et al.
patent: 2004/0057969 (2004-03-01), Smith et al.
patent: WO 97/30089 (1997-08-01), None
Lustgarten et al, Jan. 1, 1999. The Journal of Immunology. 162(1):359-65.
Wu, 2002. Clinica Chimica Acta. 322: 11-19.
Lode et al, 2000. Drugs Today (Barc). 36(5): 321-336.
Bulfone-Paus et al (1998. Cancer Research. 58: 2707-2710).
Helguera et al, 2002, Clinical Immunology, 105(3): 233-246.
Dela Cruz et al, 2005, Vaccine 23: 4793-4803.
Wells (Sep. 18, 1990) Biochemistry 29(37): 8509-8517.
Ngo et al. (Mar. 2, 1995) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 492-495.
Bork (2000) Genome Research 10:398.
Skolnick and Fetrow (2000) Trends in Biotech. 18(1): 34.
Doerks et al. (Jun. 1998) Trends in Genetics 14(6): 248.
Smith and Zhang (Nov. 1997) Nature Biotechnology 15:1222.
Brenner (Apr. 1999) Trends in Genetics 15(4): 132.
Bork and Bairoch (Oct. 1996) Trends in Genetics 12(10): 425.
Larregina et al (1997. Immunology. 91: 303-313).
Dela Cruz et al (2006; Molecular Immunology; 43: 667-676).
Braun and Pantel (1998) “Prognostic significance of micrometastatic bone marrow involvement,”Breast Cancer Research and Treatment, 52:201-216.
Bowie et al. (1990) “Deciphering the message in protein sequences: tolerance to amino acids substitutions,”Science, 247:1306-1310.
Ngo et al. (1994) “Computational complexity, protein structure prediction, and the Levinthal paradox,”The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds, Birkhauser, Boston, p. 433-506.
Pawelec (2004) “Tumour escape: antitumor effectors too much of a good thing?”Cancer lmmuunol. Imminother., 53:262-274.
Penichet et al. (1997) “Antibody-IL-2 fusion proteins: a novel strategy for immune potentiation,”Human Antibodies, 8(3):106-118.
Anselmino, et al., 1989 “Human basophils selectively express the Fc gamma RII (CDw32) subtype of IgG receptor”J Allergy Clin Immunol84:907-914.
Arai, et al., 1990 “Cytokines: coordinators of immune and inflammatory responses”Annu Rev Biochem59:783-836.
Baselga, et al., 1996 “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2
eu-overexpressing metastatic breast cancer”J Clin Oncol14:737-744.
Becker et al., 1996 “An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response” Proc Natl Acad Sci USA 93:7826-7831.
Becker et al., 1996 “Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy” J Clin Invest 98:2801-4.
Becker et al., 1996 “T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy” J Exp Med 183:2361-6.
Boyle, 1990, in Bacterial Immunoglobulin-Binding Proteins, ed. Boyle, M.P.D. (Academic, San Diego), vol. 1, pp. 17-28.
Brossart, P., et al., 2000 “Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells”Blood96:3102.
Buckle, et al., 1989 “The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors”J Immunol143:2295-2301.
Chen et al, 1998 “DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors” Cancer Res 58:1965-1971.
Chen, et al., 1995 “Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x antiCD64)”Clin Cancer Res1:1319-1325.
Colombo et al. 1992 “Local Cytokine Availability Elicicts Tumor Rejection and Systemic Immunity through Granulocyte-T-Lymphocyte Cross-Talk,”Cancer Res52:4853-4857.
Dela Cruz et al., 2000 “Recombinant anti-human HER2
eu IgG3-(GMCSF) fusion protein retains antigen specificity, cytokine function and demonstrates anti-tumor activity”J Immunol165:5112-21.
Disis 1999, “Generation of immunity to the HER-2
eu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine”Clin Cancer Res5:1289-1297.
Disis, et al 2001 “Clinical translation of peptide-based vaccine trials: the HER-2
eu model”Crit Rev Immunol21:263-273.
Disis, et al. 1996 “Peptide-based, but not whole protein, vaccines elicit immunity to HER-2
eu, oncogenic self-protein”J Immunol156:3151-3158.
Disis, et al., 1998 “HER-2
eu oncogenic protein: issues in vaccine development”,Crit Rev Immunol18:37-45.
Disis, M. L., et al., 2001 “Cancer vaccines targeting the HER2
euoncogenic protein”Semin Oncol28:12-20.
Foy, et al. 2001 “Vaccination with Her-2
eu DNA or protein subunits protects against growth of a Her-2
eu-expressing murine tumor”Vaccine19:2598-2606.
Graille M., et al. 2000, “Crystal structure of aStaphylococcus aureusprotein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity”Proc Natl Acad Sci USA97: 5399-5404.
Hartnell, et al., 1992 “IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils”J Immunol148:1471-1478.
Harvill et al., 1996 “In vivo properties of an IgG3-II-2 fusion protein. A general strategy for immune potentiation”J Immunol157:3165-70.
Hillson et al., 1993 “The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A”J Exp Med178:331-6.
Hiltbold et al., 2000, “The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells”J Immunol165:3730-41.
Hornick et al., 1997 “Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties”Blood89:4437.
Johnson, et al. “Superantigens in human disease”Scientific AmericanApr. 1992, p. 92-101.
Klebanoff, et al., 1992 “Effects of gamma-interferon on human neutrophils: protection from deterioration on storage”Blood80:225-234.
Lachman, et al. 2001 “DNA vaccination against neu reduces breast cancer incidence and metastasis in mice”Cancer Gene Ther8:259-268.
Liu et al., 1998 “Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins”Blood92:2103-2112.
Meininger et al. 2000 “Characterization of the binding interface between the E-domain of Staphylococcal protein A and an antibody Fv-fragment”Biochemistry39: 26-36.
Mire-Sluis, 1993 “Cytokines and disease,”TIBTECH11:74-77.
Murray, et al., 2000 “Clinical trials of HER-2
eu-specific vaccines”Semin Oncol27:71-75.
Nagata, et al. 1997 “Peptides derived from a wild-type murine proto-oncogene c-erbB-2? HER2
eucan induce CTL and tumor suppression in syngeneic hosts”J Immunol159:1336.
Peng et al., 1999, “A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity”J Immunol163:250-8.
Penichet et al., 1998 “An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor
Dela Cruz Jay
Morrison Sherie L.
Peng Lisan
Penichet Manuel L.
Bunner Bridget E
Howard Zachary C
Littlepage Paul
Quine Intellectual Property Law Group P.C.
The Regents of the University of California
LandOfFree
Antibody fusion proteins: effective adjuvants of protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody fusion proteins: effective adjuvants of protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody fusion proteins: effective adjuvants of protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242700